Shares of Reckitt Benckiser Group Plc (LON:RB) have been assigned an average rating of “Hold” from the twenty-one analysts that are presently covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is GBX 6,791.67 ($88.75).
A number of research firms have recently weighed in on RB. Liberum Capital reissued a “buy” rating on shares of Reckitt Benckiser Group in a research note on Tuesday. UBS Group reissued a “neutral” rating on shares of Reckitt Benckiser Group in a research note on Friday. JPMorgan Chase & Co. reissued an “overweight” rating and issued a GBX 9,000 ($117.60) price target on shares of Reckitt Benckiser Group in a research note on Thursday, October 25th. Morgan Stanley reissued a “buy” rating on shares of Reckitt Benckiser Group in a research note on Tuesday, October 16th. Finally, Goldman Sachs Group set a GBX 7,025 ($91.79) price target on Reckitt Benckiser Group and gave the company a “neutral” rating in a research note on Monday, October 8th.
Shares of RB opened at GBX 6,276 ($82.01) on Tuesday. Reckitt Benckiser Group has a 52 week low of GBX 5,562 ($72.68) and a 52 week high of GBX 8,110.43 ($105.98).
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
See Also: Penny Stocks, What You Need To Know
Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.